NEW YORK (GenomeWeb News) – Molecular diagnostics developer Trovagene today said that it has closed on a registered direct offering of $15 million of its common stock to an institutional investor at $7 per share.

Separately, the company and RainDance Technologies said earlier in the week that Trovagene has adopted RainDance's RainDrop Digital PCR System for R&D work.

Net proceeds from its $15 million offering will be used for R&D activities, working capital, and general corporate purposes, Trovagene said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
21
Sponsored by
Roche

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.